title: Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.
abstract: The improved recognition of pathogenetic molecular mechanisms has led to the use of drugs targeting cytokines in different inflammatory arthropathies as well psoriatic arthritis (PsA). In particular, the progress in knowledge on tumor necrosis factor (TNF)-α in the pathogenesis of PsA has changed the therapeutic approach by use of direct and receptor cytokine antagonists. Currently, infliximab (IFX), adalimumab, etanercept, golimumab and certolizumab pegol represent the five anti-TNF-α available for the treatment of PsA. This review describes evidence on treatment aimed at neutralizing TNF-α in PsA patients, from the first study in 2000 until today, mainly derived from randomized clinical trials. In comparison with traditional therapies, anti-TNF-α agents have shown to have more efficacy both in treating clinical aspects, including enthesitis, dactylitis, joint pain and swelling, axial involvement, nail and skin lesions, and in reducing radiographic progression. Moreover, anti-TNF-α agents have been demonstrated to be reasonably safe in PsA, as confirmed by data derived by different registries.
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.|b Rheumatology Unit, Department of Medicine DIMED , University of Padova , Padova , Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Caso
authors.affiliation: c Department of Medicine and Health Sciences "Vincenzo Tiberio" , University of Molise , Campobasso , Italy.
authors.forename: Ennio
authors.initials: E
authors.lastname: Lubrano
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Del Puente
authors.affiliation: d Geriatric Unit, Faculty of Medicine and Psychology , "Sapienza" University of Rome, S. Andrea Hospital , Rome , Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Caso
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
authors.forename: Rosario
authors.initials: R
authors.lastname: Peluso
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Foglia
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
authors.forename: Carolina
authors.initials: C
authors.lastname: Benigno
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
authors.forename: Nicolò
authors.initials: N
authors.lastname: Girolimetto
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Bottiglieri
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Scarpa
authors.affiliation: a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.|b Rheumatology Unit, Department of Medicine DIMED , University of Padova , Padova , Italy.
authors.forename: Luisa
authors.initials: L
authors.lastname: Costa
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000276:immunology / Q000628:therapy*; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha
keywords: TNF-α; adalimumab; anti-TNF-α; certolizumab; etanercept; golimumab; infliximab; psoriatic arthritis; therapy